[go: up one dir, main page]

DE69029934D1 - Aus dem gehirn stammender neurotropher faktor - Google Patents

Aus dem gehirn stammender neurotropher faktor

Info

Publication number
DE69029934D1
DE69029934D1 DE69029934T DE69029934T DE69029934D1 DE 69029934 D1 DE69029934 D1 DE 69029934D1 DE 69029934 T DE69029934 T DE 69029934T DE 69029934 T DE69029934 T DE 69029934T DE 69029934 D1 DE69029934 D1 DE 69029934D1
Authority
DE
Germany
Prior art keywords
bdnf
nucleic acid
ngf
acid sequences
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69029934T
Other languages
English (en)
Other versions
DE69029934T2 (de
Inventor
Carolyn Hyman
Ralph Alderson
George Yancopoulos
Yves-Alain Barde
Hans Thoenen
Andreas Hohn
Friedrich Lottspeich
Ronald Lindsay
Magdalena Hofer
Joachim Leibrock
David Edgar
Bastian Hengerer
Dan Lindholm
Francisco Zafra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/400,591 external-priority patent/US5180820A/en
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften, Regeneron Pharmaceuticals Inc filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of DE69029934D1 publication Critical patent/DE69029934D1/de
Publication of DE69029934T2 publication Critical patent/DE69029934T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69029934T 1989-08-30 1990-08-29 Aus dem gehirn stammender neurotropher faktor Expired - Lifetime DE69029934T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor
US07/570,657 US5229500A (en) 1989-08-30 1990-08-20 Brain derived neurotrophic factor
PCT/US1990/004915 WO1991003568A1 (en) 1989-08-30 1990-08-29 Brain derived neurotrophic factor

Publications (2)

Publication Number Publication Date
DE69029934D1 true DE69029934D1 (de) 1997-03-27
DE69029934T2 DE69029934T2 (de) 1997-07-24

Family

ID=27017110

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69029934T Expired - Lifetime DE69029934T2 (de) 1989-08-30 1990-08-29 Aus dem gehirn stammender neurotropher faktor

Country Status (20)

Country Link
US (2) US5229500A (de)
EP (1) EP0440777B1 (de)
KR (1) KR100188189B1 (de)
CN (1) CN1124343C (de)
AT (1) ATE148921T1 (de)
AU (1) AU647412B2 (de)
CA (1) CA2040412C (de)
DE (1) DE69029934T2 (de)
DK (1) DK0440777T3 (de)
ES (1) ES2098271T3 (de)
FI (1) FI105342B (de)
HK (1) HK1006578A1 (de)
IE (1) IE903128A1 (de)
IL (1) IL95512A0 (de)
LV (1) LV10725B (de)
NO (1) NO303584B1 (de)
PT (1) PT95152B (de)
SG (1) SG46954A1 (de)
SK (1) SK422990A3 (de)
WO (1) WO1991003568A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844072A (en) * 1992-05-26 1998-12-01 University Of California Antibiotic cryptdin peptides and methods of their use
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US6780837B1 (en) * 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IL95511A (en) 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
AU2010592A (en) * 1991-05-20 1992-12-30 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
JPH06509333A (ja) * 1991-07-03 1994-10-20 リジェネロン　ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン活性に対する方法およびアッセイ系
ATE202939T1 (de) * 1991-07-10 2001-07-15 Regeneron Pharma Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
AU677951B2 (en) * 1992-02-14 1997-05-15 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
CA2137377C (en) * 1992-06-04 2011-03-08 Lincoln V. Johnson Retinal pigmented epithelium derived neurotrophic factor
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
ATE206056T1 (de) * 1992-06-08 2001-10-15 Takeda Chemical Industries Ltd Therapeutisches agens für neutropenie
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
DE69328025T2 (de) * 1992-09-03 2000-11-02 Regeneron Pharmaceuticals, Inc. Dorsalgewebe beeinflussender faktor und zusammensetzungen
DK0662146T3 (da) * 1992-09-03 2000-11-13 Univ California Dorsalvævpåvirkende faktor og præparat
US20040224409A1 (en) * 1992-09-25 2004-11-11 Laurent Pradier Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
AU7605394A (en) * 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1995012686A1 (en) * 1993-11-03 1995-05-11 Cephalon, Inc. Method for screening for compounds which change the tyrosine hydroxylase content of intact cells in culture
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
AU708529B2 (en) * 1994-11-10 1999-08-05 University Of Kentucky Research Foundation, The Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US6743628B1 (en) * 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
WO1998003546A1 (en) * 1996-07-19 1998-01-29 Amgen Inc. Analogs of cationic proteins
US6005081A (en) 1996-11-15 1999-12-21 Genentech, Inc. Purification of recombinant human neurotrophins
US6391312B1 (en) 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes
EP1029051A1 (de) * 1997-11-11 2000-08-23 Universiteit Utrecht Genen mit beschränkten expression in mesencephalischen dopaminergischen neuronen
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
DE69939484D1 (de) * 1998-10-28 2008-10-16 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
AU780408B2 (en) * 1999-06-08 2005-03-17 Calibre Biotechnology Pty Limited Small cyclic mimics of brain-derived neurotrophic factor (BDNF)
WO2001019851A2 (en) * 1999-09-16 2001-03-22 Neurotrophic Bioscience Inc. Opaminergic neuronal survival-promoting factors and uses thereof
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
US6784335B2 (en) 2000-06-29 2004-08-31 Deltagen, Inc. Transgenic mice containing BMP gene disruptions
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7491810B2 (en) 2001-11-30 2009-02-17 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US7615676B2 (en) 2001-11-30 2009-11-10 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
AU2003286833A1 (en) * 2002-11-01 2004-06-07 University Of Medicine And Dentistry Of New Jersey A method for increasing synaptic growth or plasticity
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
EP1671641B1 (de) * 2003-09-09 2013-11-06 Two Cells Co., Ltd Heilmittel und therapeutisches verfahren für periodontal-erkrankungen und erkrankungen der pulpa
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
EP2395101B1 (de) * 2005-05-02 2013-11-13 University of Southern California Mit CpG-Insel-Methylatorphänotyp (CIMP) in menschlichem Kolorektalkrebs assoziierte DNA-Methylierungsmarker
WO2006134602A2 (en) 2005-06-16 2006-12-21 Ramot At Tel Aviv University Ltd. Isolated cells and populations comprising same for the treatment of cns diseases
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
WO2007066338A1 (en) * 2005-12-08 2007-06-14 Ramot At Tel Aviv University Ltd. Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases
US20100035877A1 (en) * 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
WO2009144718A1 (en) 2008-05-28 2009-12-03 Ramot At Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP3533467B1 (de) 2009-10-09 2023-07-26 Armagen, Inc. Verfahren und zusammensetzungen zur erhöhung der iduronat-2-sulfatase-aktivität im zns
EP2594295A1 (de) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Nervenimplantat basierend auf einem kompaktierten, zellhaltigen Biomaterial
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
AU2018325842A1 (en) * 2017-08-28 2020-04-16 Shanghai Yile Biotechnology Co, . Ltd. Polypeptide and antibody bound to polypeptide
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
CN116543838B (zh) * 2023-07-05 2023-09-05 苏州凌点生物技术有限公司 一种生物基因选择表达概率的数据分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3123963C2 (de) * 1981-06-19 1985-05-15 Berchem & Schaberg Gmbh, 4650 Gelsenkirchen Gesteinsschneidkopf für einen Schneidkopf-Saugbagger
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins

Also Published As

Publication number Publication date
CA2040412C (en) 2003-03-18
PT95152A (pt) 1991-05-22
CN1124343C (zh) 2003-10-15
PT95152B (pt) 1998-06-30
LV10725A (lv) 1995-06-20
AU647412B2 (en) 1994-03-24
ATE148921T1 (de) 1997-02-15
KR100188189B1 (en) 1999-06-01
DK0440777T3 (da) 1997-04-21
LV10725B (en) 1995-12-20
CN1052142A (zh) 1991-06-12
US5229500A (en) 1993-07-20
NO911689D0 (no) 1991-04-29
KR920701432A (ko) 1992-08-11
EP0440777B1 (de) 1997-02-12
ES2098271T3 (es) 1997-05-01
DE69029934T2 (de) 1997-07-24
IL95512A0 (en) 1991-06-30
SG46954A1 (en) 1998-03-20
SK279668B6 (sk) 1999-02-11
EP0440777A1 (de) 1991-08-14
SK422990A3 (en) 1999-02-11
WO1991003568A1 (en) 1991-03-21
AU6337390A (en) 1991-04-08
EP0440777A4 (en) 1992-05-13
IE903128A1 (en) 1991-03-13
HK1006578A1 (en) 1999-03-05
FI912104A0 (fi) 1991-04-30
CA2040412A1 (en) 1991-03-01
NO303584B1 (no) 1998-08-03
US5438121A (en) 1995-08-01
FI105342B (fi) 2000-07-31
NO911689L (no) 1991-06-25

Similar Documents

Publication Publication Date Title
DE69029934D1 (de) Aus dem gehirn stammender neurotropher faktor
GR900100653A (el) Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο.
Maruyama et al. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells
EP0448707A4 (en) Ciliary neurotrophic factor
ATE94547T1 (de) Pharmazeutische zubereitung enthaltend eine tetrahydropyrrolverbindung als aktiven bestandteil und verfahren zur herstellung dieser tetrapyrrolverbindung.
DK0414275T3 (da) Fremgangsmåde til fremtilling af cycliske aminosyrederivater samt mellemprodukter
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
FR2637612B1 (fr) Sequences de nucleotides codant pour une proteine a activite ureasique
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
ATE106748T1 (de) Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
EP0192988A3 (en) Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
DE4423392A1 (de) Verfahren zur Identifizierung antigener Peptide
ES2009689A6 (es) Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
DE938329T1 (de) Immunogene tlp-zusammensetzung
ATE317021T1 (de) Antisense modulierung von lfa-3
Barde et al. Brain derived neurotrophic factor
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
Harada et al. Karyotypes of two species of Insectivora from Taiwan (Insectivora, Soricidae)
Belluardo et al. Effect of cerebral hemisphere decortication on the cytotoxic activity of natural killer and natural cytotoxic lymphocytes in the mouse
WO2002060928A3 (en) Medane genes and proteins
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof
DE3722673A1 (de) Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: REGENERON PHARMACEUTICALS, INC., TARRYTOWN, N.Y.,